Torcetrapib: Biomarker for the Big Pharma Business Model
Generate a summary of this article
Listen to this article
As biotechs often live or die on the success of one pipeline project, so too Pfizer finds itself in the same position. Weak drug launches, intense competition in its core cholesterol franchise, and, analysts say, an unimpressive pipeline. Except torcetrapib--perhaps the most important clinical-stage project in the industry. If it fails, Pfizer's in trouble. If it succeeds, Pfizer will have proven that giantism isn't antithetical to growth.
The pharmaceutical world is considering the unthinkable: is
Pfizer Inc. vulnerable? Investors have
fled the stock; it faces huge patent challenges; its most important
franchise—cholesterol-reduction—is facing a concerted
challenge from a fast-growing new combination product,
simvastatin/ezetimibe (Vytorin) from Schering-Plough
Corp. and Merck & Co. Inc. Most of its recent drug launches have
sputtered. And analysts don't see many new big drugs in its
pipeline.
Except torcetrapib—perhaps the most important clinical-stage project in the industry because it is designed to replace the industry's most important...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
